Upstream Bio Inc
UPB29.480USD
-0.790-2.61%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.59BMarket Cap
LossP/E TTM
More Details of Upstream Bio Inc Company
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Upstream Bio Inc Info
Ticker SymbolUPB
Company nameUpstream Bio Inc
IPO dateOct 11, 2024
CEOSutherland (E. Rand)
Number of employees52
Security typeOrdinary Share
Fiscal year-endOct 11
Address890 Winter Street, Suite 200
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone17812082466
Websitehttps://upstreambio.com/
Ticker SymbolUPB
IPO dateOct 11, 2024
CEOSutherland (E. Rand)
Company Executives of Upstream Bio Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Stacy Price
Ms. Stacy Price
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Independent Director
Independent Director
--
--
Mr. Michael Paul (Mike) Gray
Mr. Michael Paul (Mike) Gray
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Adam Houghton, Ph.D.
Dr. Adam Houghton, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Andy Wardle
Dr. Andy Wardle
Independent Director
Independent Director
--
--
Mr. Atsushi Sugita
Mr. Atsushi Sugita
Independent Director
Independent Director
--
--
Mr. Erez Chimovits
Mr. Erez Chimovits
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Ronald C. (Ron) Renaud, Jr.
Mr. Ronald C. (Ron) Renaud, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Stacy Price
Ms. Stacy Price
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Independent Director
Independent Director
--
--
Mr. Michael Paul (Mike) Gray
Mr. Michael Paul (Mike) Gray
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Adam Houghton, Ph.D.
Dr. Adam Houghton, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Andy Wardle
Dr. Andy Wardle
Independent Director
Independent Director
--
--
Mr. Atsushi Sugita
Mr. Atsushi Sugita
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
937.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.50%
OrbiMed Advisors, LLC
10.54%
Access Industries, Inc.
10.17%
Decheng Capital LLC
6.08%
Norges Bank Investment Management (NBIM)
5.33%
Other
53.38%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.50%
OrbiMed Advisors, LLC
10.54%
Access Industries, Inc.
10.17%
Decheng Capital LLC
6.08%
Norges Bank Investment Management (NBIM)
5.33%
Other
53.38%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.51%
Corporation
14.72%
Venture Capital
12.53%
Investment Advisor/Hedge Fund
11.86%
Private Equity
10.54%
Hedge Fund
6.76%
Sovereign Wealth Fund
5.33%
Research Firm
0.77%
Bank and Trust
0.07%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
146
50.98M
94.34%
+856.75K
2025Q2
141
56.33M
104.50%
+7.82M
2025Q1
136
58.61M
109.21%
+10.01M
2024Q4
100
57.72M
107.69%
+27.36M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
7.69M
14.27%
+533.47K
+7.45%
Jun 30, 2025
OrbiMed Advisors, LLC
5.69M
10.56%
--
--
Jun 30, 2025
Access Industries, Inc.
5.49M
10.19%
+5.49M
--
Oct 15, 2024
Decheng Capital LLC
3.29M
6.09%
--
--
Jun 30, 2025
Norges Bank Investment Management (NBIM)
969.92K
1.8%
-30.08K
-3.01%
Jun 30, 2025
Enavate Sciences GP, LLC
2.46M
4.56%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.17M
4.03%
+1.26M
+139.34%
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
2.44M
4.53%
+144.22K
+6.28%
Jun 30, 2025
HBM Partners AG
2.72M
5.04%
--
--
Dec 31, 2024
TCG Crossover Management, LLC
2.80M
5.2%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.51%
ALPS Medical Breakthroughs ETF
0.58%
State Street SPDR S&P Biotech ETF
0.27%
Fidelity Fundamental Small-Mid Cap ETF
0.24%
iShares Health Innovation Active ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Avantis US Small Cap Equity ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.07%
iShares Russell 2000 Value ETF
0.06%
ProShares Hedge Replication ETF
0.04%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.51%
ALPS Medical Breakthroughs ETF
Proportion0.58%
State Street SPDR S&P Biotech ETF
Proportion0.27%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.24%
iShares Health Innovation Active ETF
Proportion0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.13%
Avantis US Small Cap Equity ETF
Proportion0.1%
Fidelity Enhanced Small Cap ETF
Proportion0.07%
iShares Russell 2000 Value ETF
Proportion0.06%
ProShares Hedge Replication ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Upstream Bio Inc?
The top five shareholders of Upstream Bio Inc are:
Fidelity Management & Research Company LLC holds 7.69M shares, accounting for 14.27% of the total shares.
OrbiMed Advisors, LLC holds 5.69M shares, accounting for 10.56% of the total shares.
Access Industries, Inc. holds 5.49M shares, accounting for 10.19% of the total shares.
Decheng Capital LLC holds 3.29M shares, accounting for 6.09% of the total shares.
Norges Bank Investment Management (NBIM) holds 969.92K shares, accounting for 1.80% of the total shares.
Fidelity Management & Research Company LLC holds 7.69M shares, accounting for 14.27% of the total shares.
OrbiMed Advisors, LLC holds 5.69M shares, accounting for 10.56% of the total shares.
Access Industries, Inc. holds 5.49M shares, accounting for 10.19% of the total shares.
Decheng Capital LLC holds 3.29M shares, accounting for 6.09% of the total shares.
Norges Bank Investment Management (NBIM) holds 969.92K shares, accounting for 1.80% of the total shares.
What are the top three shareholder types of Upstream Bio Inc?
The top three shareholder types of Upstream Bio Inc are:
Fidelity Management & Research Company LLC
OrbiMed Advisors, LLC
Access Industries, Inc.
Fidelity Management & Research Company LLC
OrbiMed Advisors, LLC
Access Industries, Inc.
How many institutions hold shares of Upstream Bio Inc (UPB)?
As of 2025Q3, 146 institutions hold shares of Upstream Bio Inc, with a combined market value of approximately 50.98M, accounting for 94.34% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.16%.
What is the biggest source of revenue for Upstream Bio Inc?
In FY2025Q2, the -- business generated the highest revenue for Upstream Bio Inc, amounting to -- and accounting for --% of total revenue.
